Immunic's IMU-856 shows dose-dependent GLP-1 increase in celiac trial; preclinical weight loss

IMMUNIC, INC.

Post-hoc phase 1b analysis: dose-dependent GLP-1 increase up to 250% vs placebo; p=0.014 (80mg) and p=0.003 (160mg).
Preclinical 6-month study: IMU-856 reduced body weight gain and food consumption up to -40% vs control in a dose-dependent manner.
Program is Phase 2 ready; company plans to explore IMU-856 as oral treatment for obesity (market >$170B by 2031).
Data also presented at ECCO 2025 digital oral presentation; webcast held Feb 20, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.